Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 13/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.41 |
| ▸ | PDE4A | P27815 | 11/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6657877 | 0.97 | PDE4B (0.41) | PDE4BPDE4DPDE4APDE4CAXL | |
| SCHEMBL6841686 | 0.93 | SMN1; SMN2 (0.45) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL6657024 | 0.93 | PDE4D (0.47) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL6662451 | 0.91 | PDE4D (0.42) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL6655321 | 0.91 | PDE4D (0.44) | PDE4BPDE4DPDE4APDE4CAXL | |
| SCHEMBL6837633 | 0.90 | SMN1; SMN2 (0.45) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL6659644 | 0.90 | PDE4D (0.43) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL6660677 | 0.90 | NPC1 (0.45) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL6658138 | 0.90 | PDE4D (0.41) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL6837841 | 0.90 | ABL1 (0.44) | PDE4BPDE4DPDE4APDE4CPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2004-11-25 | — | — | US | disclosed |
| EP-0763534-B1 | Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors | MERCK PATENT GMBH (DE) | 2003-02-26 | — | — | EP | disclosed |
| US-5859008-A | Arylalkyl diazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-01-12 | — | — | US | disclosed |
| EP-0763534-A1 | Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors | MERCK PATENT GmbH (DE) | 1997-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | PDE4A, PDE3A, PDE3B | PDE4B 4/4885PDE4D 12/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.